IRL 2500

• UNSPSC Description:

  IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50?values of 1.3 and 94 nM for ETB?and ETA?receptors, respectively. IRL 2500 inhibits ETB?receptor-mediated blood pressure increase and renal vascular resistance in rats?in vivo[1].

• Target Antigen:

  Endothelin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/irl-2500.html

• Purity:

  99.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC([C@@H](CC3=CC=C(C4=CC=CC=C4)C=C3)N(C(C5=CC(C)=CC(C)=C5)=O)C)=O

• Molecular Weight:

  573.68

• References & Citations:

  [1]Balwierczak JL, et al. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.J Cardiovasc Pharmacol. 1995;26 Suppl 3:S393-6.|[2]Webb RL, et al. Effects of the ETB-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats.J Cardiovasc Pharmacol. 1995;26 Suppl 3:S389-92.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  169545-27-1